- Home
- ILLR vs ALDX Comparison
ILLR vs ALDX Comparison
Compare ILLR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- ALDX
- Stock Information
- Founded
- ILLR 2015
- ALDX 2004
- Country
- ILLR United States
- ALDX United States
- Employees
- ILLR N/A
- ALDX N/A
- Industry
- ILLR Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- ALDX Health Care
- Exchange
- ILLR Nasdaq
- ALDX Nasdaq
- Market Cap
- ILLR 304.1M
- ALDX 304.9M
- IPO Year
- ILLR N/A
- ALDX 2014
- Fundamental
- Price
- ILLR $0.79
- ALDX $6.58
- Analyst Decision
- ILLR
- ALDX Strong Buy
- Analyst Count
- ILLR 0
- ALDX 2
- Target Price
- ILLR N/A
- ALDX $10.00
- AVG Volume (30 Days)
- ILLR 567.6K
- ALDX 666.8K
- Earning Date
- ILLR 03-25-2025
- ALDX 05-01-2025
- Dividend Yield
- ILLR N/A
- ALDX N/A
- EPS Growth
- ILLR N/A
- ALDX N/A
- EPS
- ILLR N/A
- ALDX N/A
- Revenue
- ILLR $45,244,000.00
- ALDX N/A
- Revenue This Year
- ILLR N/A
- ALDX N/A
- Revenue Next Year
- ILLR N/A
- ALDX N/A
- P/E Ratio
- ILLR N/A
- ALDX N/A
- Revenue Growth
- ILLR N/A
- ALDX N/A
- 52 Week Low
- ILLR $0.66
- ALDX $2.75
- 52 Week High
- ILLR $8.86
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- ALDX 53.63
- Support Level
- ILLR N/A
- ALDX $6.22
- Resistance Level
- ILLR N/A
- ALDX $6.87
- Average True Range (ATR)
- ILLR 0.00
- ALDX 0.46
- MACD
- ILLR 0.00
- ALDX -0.03
- Stochastic Oscillator
- ILLR 0.00
- ALDX 60.51
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.